Plasma Aβ42 as a Biomarker of Prodromal Alzheimer's Disease Progression in Patients with Amnestic Mild Cognitive Impairment: Evidence from the PharmaCog/E-ADNI Study

Journal of Alzheimer's Disease : JAD
Diego AlbaniPharmaCog Consortium

Abstract

It is an open issue whether blood biomarkers serve to diagnose Alzheimer's disease (AD) or monitor its progression over time from prodromal stages. Here, we addressed this question starting from data of the European FP7 IMI-PharmaCog/E-ADNI longitudinal study in amnesic mild cognitive impairment (aMCI) patients including biological, clinical, neuropsychological (e.g., ADAS-Cog13), neuroimaging, and electroencephalographic measures. PharmaCog/E-ADNI patients were classified as "positive" (i.e., "prodromal AD" n = 76) or "negative" (n = 52) based on a diagnostic cut-off of Aβ42/P-tau in cerebrospinal fluid as well as APOE ε 4 genotype. Blood was sampled at baseline and at two follow-ups (12 and 18 months), when plasma amyloid peptide 42 and 40 (Aβ42, Aβ40) and apolipoprotein J (clusterin, CLU) were assessed. Linear Mixed Models found no significant differences in plasma molecules between the "positive" (i.e., prodromal AD) and "negative" groups at baseline. In contrast, plasma Aβ42 showed a greater reduction over time in the prodromal AD than the "negative" aMCI group (p = 0.048), while CLU and Aβ40 increased, but similarly in the two groups. Furthermore, plasma Aβ42 correlated with the ADAS-Cog13 score both in aMCI patients as a...Continue Reading

References

Apr 12, 2001·Journal of Clinical Epidemiology·R Bender, S Lange
Sep 25, 2007·Neurobiology of Aging·Miroslaw BrysMony J de Leon
Oct 16, 2007·Neuroscience Letters·Vilmantas GiedraitisLars Lannfelt
Jun 18, 2010·Archives of Neurology·Minerva M CarrasquilloSteven G Younkin
Jul 7, 2010·Archives of General Psychiatry·Madhav ThambisettySimon Lovestone
Apr 7, 2011·JAMA : the Journal of the American Medical Association·Elisabeth M C SchrijversMonique M B Breteler
Jul 4, 2012·Alzheimer's & Dementia : the Journal of the Alzheimer's Association·Michal J FigurskiUNKNOWN Alzheimer’s Disease Neuroimaging Initiative
Mar 9, 2013·Alzheimer's Research & Therapy·Jon B ToledoJohn Q Trojanowski
Jan 1, 2014·JAMA Neurology·Rahul S DesikanUNKNOWN Alzheimer’s Disease Neuroimaging Initiative Group
May 23, 2014·Lancet Neurology·Bruno DuboisJeffrey L Cummings
Sep 25, 2015·Journal of Alzheimer's Disease : JAD·Wesley JongbloedRobert Veerhuis
Mar 27, 2016·Alzheimer's & Dementia : the Journal of the Alzheimer's Association·Lei YuDavid A Bennett
May 31, 2016·Alzheimer's & Dementia : Diagnosis, Assessment & Disease Monitoring·Veer Bala GuptaUNKNOWN AIBL Research Group
Jun 1, 2016·Scientific Reports·Shorena JanelidzeOskar Hansson
Jan 11, 2017·Alzheimer's & Dementia : the Journal of the Alzheimer's Association·Hugo LövheimSture Eriksson
Feb 17, 2017·Neurobiology of Aging·Katie LunnonUNKNOWN AddNeuroMed Consortium
May 17, 2017·Alzheimer's & Dementia : Diagnosis, Assessment & Disease Monitoring·Veer Bala GuptaUNKNOWN AIBL Research Group
Jul 25, 2017·Alzheimer's & Dementia : the Journal of the Alzheimer's Association·Vitaliy OvodRandall J Bateman
Sep 22, 2017·Human Molecular Genetics·Subodh KumarP Hemachandra Reddy
Sep 28, 2017·Alzheimer's & Dementia : Diagnosis, Assessment & Disease Monitoring·Noelia FandosUNKNOWN AIBL Research Group
Nov 11, 2017·Alzheimer's & Dementia : Translational Research & Clinical Interventions·Diane M JacobsSteven D Edland
Feb 9, 2018·Nature·Akinori NakamuraKatsuhiko Yanagisawa
Feb 20, 2018·Alzheimer's & Dementia : the Journal of the Alzheimer's Association·Olivier HanonUNKNOWN BALTAZAR study group
Apr 5, 2018·Journal of Alzheimer's Disease : JAD·Charlotte E TeunissenKaj Blennow
Apr 8, 2018·EMBO Molecular Medicine·Andreas NabersHermann Brenner
Apr 8, 2018·Alzheimer's & Dementia : the Journal of the Alzheimer's Association·Michelle M MielkeJeffrey L Dage
Apr 15, 2018·Alzheimer's & Dementia : the Journal of the Alzheimer's Association·Clifford R JackUNKNOWN Contributors
May 16, 2018·Journal of Alzheimer's Disease : JAD·Henrik Zetterberg, Kaj Blennow

❮ Previous
Next ❯

Citations

Jul 16, 2019·Journal of Neuropathology and Experimental Neurology·Mahsa MayeliFarzaneh Rahmani
Dec 8, 2019·The Journal of Applied Laboratory Medicine·Xuemei ZhaoOmar F Laterza
Aug 7, 2019·Alzheimer's & Dementia : Diagnosis, Assessment & Disease Monitoring·Shannon L RisacherLiana G Apostolova
Apr 9, 2019·Journal of Alzheimer's Disease : JAD·Moira MarizzoniUNKNOWN PharmaCog Consortium
Dec 18, 2020·JAMA Network Open·Kelly Virecoulon GiudiciUNKNOWN MAPT/DSA Group
Dec 1, 2020·Journal of Alzheimer's Disease : JAD·Pankaj D MehtaThomas Wisniewski
May 8, 2021·Scientific Reports·Elisabeth H ThijssenCharlotte E Teunissen

❮ Previous
Next ❯

Related Concepts

Related Feeds

Alzheimer's Disease: APOE

Apolipoprotein E (APOE) polymorphic alleles are major genetic risk factors for Alzheimer's disease. Discover the latest research on APOE and other genetic determinants of Alzheimer's disease here.

CSF & Lymphatic System

This feed focuses on Cerebral Spinal Fluid (CSF) and the lymphatic system. Discover the latest papers using imaging techniques to track CSF outflow into the lymphatic system in animal models.

Alzheimer's Disease: Neuroimaging

Neuroimaging can help identify pathological hallmarks of Alzheimer's disease (AD). Here is the latest research on neuroimaging modalities, including magnetic resonance imaging and positron emission tomography, in AD.

ApoE Phenotypes

Apolipoprotein E (APOE) is a protein involved in fat metabolism and associated with the pathogenesis of Alzheimer's disease and cardiovascular disease. Here is the latest research on APOE phenotypes.

Alzheimer's Disease: APP

Amyloid precursor protein (APP) proteolysis is critical for the development of Alzheimer's disease, a neurodegenerative disease associated with accumulation of amyloid plaques in the brain. Here is the latest research on APP and Alzheimer's disease.

Alzheimer's Disease: Tau & TDP-43

Alzheimer's disease is a neurodegenerative disease. This feed focuses on the underlying role of tau proteins and TAR DNA-binding protein 43, as well as other genetic factors, in Alzheimer's disease.

Alzheimer's Disease: Amyloid Beta

Alzheimer's disease is a neurodegenerative disease associated with the accumulation of amyloid plaques in the brain; these plaques are comprised of amyloid beta deposits. Here is the latest research in this field.